


Claims

1. A compound of Formula (I):



(I)

or a pharmaceutically acceptable salt thereof, where:

R¹ is methyl;

R² is hydro or methyl; or **R¹** and **R²** together with the nitrogen atom to which they are bonded form an azetidiny, pyrrolidiny or piperidiny ring;

R³ is hydro or fluoro;

R⁴ is hydro or methyl; and

R⁵ is hydro or fluoro.

2. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1, where **R¹** and **R²** are both methyl; or **R¹** and **R²** together with the nitrogen atom to which they are bonded form an azetidiny, pyrrolidiny or piperidiny ring.
3. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1 or claim 2, where **R¹** and **R²** together with the nitrogen atom to which they are bonded form an azetidiny, pyrrolidiny or piperidiny ring.
4. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of the preceding claims, where **R³** is hydro.
5. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of the preceding claims, where **R⁴** is methyl.

6. The compound of Formula **(I)**, or a pharmaceutically acceptable salt thereof as claimed in any one of the preceding claims, where **R⁵** is fluoro.

5 7. The compound of Formula **(I)**, or a pharmaceutically acceptable salt thereof, as claimed in claim 1, where:

R¹ is methyl;

R² is methyl; or **R¹** and **R²** together with the nitrogen atom to which they are bonded form an azetidiny, pyrrolidinyl or piperidinyl ring;

10 **R³** is hydro or fluoro;

R⁴ is methyl; and

R⁵ is hydro or fluoro.

15 8. The compound of Formula **(I)**, or a pharmaceutically acceptable salt thereof, as claimed in claim 1, where the compound is selected from the group consisting of:

8-[6-[3-(Dimethylamino)propoxy]-3-pyridyl]-7-fluoro-1-isopropyl-3-methyl-imidazo[4,5-c]quinolin-2-one;

7-Fluoro-1-isopropyl-3-methyl-8-[6-[3-(1-piperidyl)propoxy]-3-pyridyl]imidazo[4,5-c]quinolin-2-one;

20 7-Fluoro-1-isopropyl-3-methyl-8-[6-(3-pyrrolidin-1-ylpropoxy)-3-pyridyl]imidazo[4,5-c]quinolin-2-one;

8-[6-[3-(azetidin-1-yl)propoxy]-3-pyridyl]-7-fluoro-1-isopropyl-3-methyl-imidazo[4,5-c]quinolin-2-one;

25 1-Isopropyl-3-methyl-8-[6-[3-(1-piperidyl)propoxy]-3-pyridyl]imidazo[4,5-c]quinolin-2-one;

8-[6-[3-(dimethylamino)propoxy]-3-pyridyl]-1-isopropyl-3-methyl-imidazo[4,5-c]quinolin-2-one;

1-isopropyl-3-methyl-8-[6-(3-pyrrolidin-1-ylpropoxy)-3-pyridyl]imidazo[4,5-c]quinolin-2-one;

30 8-[6-[3-(Azetidin-1-yl)propoxy]-3-pyridyl]-1-isopropyl-3-methyl-imidazo[4,5-c]quinolin-2-one;

8-[2-Fluoro-6-[3-(1-piperidyl)propoxy]-3-pyridyl]-1-isopropyl-3-methyl-imidazo[4,5-c]quinolin-2-one;

8-[6-[3-(dimethylamino)propoxy]-2-fluoro-3-pyridyl]-1-isopropyl-3-methyl-imidazo[4,5-c]quinolin-2-one;

5 8-[6-[3-(dimethylamino)propoxy]-2-fluoro-3-pyridyl]-7-fluoro-1-isopropyl-3-methyl-imidazo[4,5-c]quinolin-2-one;

8-[2-fluoro-6-(3-pyrrolidin-1-ylpropoxy)-3-pyridyl]-1-isopropyl-3-methyl-imidazo[4,5-c]quinolin-2-one;

10 7-fluoro-8-[2-fluoro-6-(3-pyrrolidin-1-ylpropoxy)-3-pyridyl]-1-isopropyl-3-methyl-imidazo[4,5-c]quinolin-2-one;

7-fluoro-8-[2-fluoro-6-[3-(1-piperidyl)propoxy]-3-pyridyl]-1-isopropyl-3-methyl-imidazo[4,5-c]quinolin-2-one;

8-[6-[3-(azetidin-1-yl)propoxy]-2-fluoro-3-pyridyl]-1-isopropyl-3-methyl-imidazo[4,5-c]quinolin-2-one;

15 8-[6-[3-(azetidin-1-yl)propoxy]-2-fluoro-3-pyridyl]-7-fluoro-1-isopropyl-3-methyl-imidazo[4,5-c]quinolin-2-one;

8-[6-[3-(Dimethylamino)propoxy]-3-pyridyl]-7-fluoro-1-isopropyl-3H-imidazo[4,5-c]quinolin-2-one; and

20 7-Fluoro-1-isopropyl-8-[6-[3-(1-piperidyl)propoxy]-3-pyridyl]-3H-imidazo[4,5-c]quinolin-2-one.

9. The compound of Formula **(I)** as claimed in claim 1, wherein the compound is 7-fluoro-1-isopropyl-3-methyl-8-[6-[3-(1-piperidyl)propoxy]-3-pyridyl]imidazo[4,5-c]quinolin-2-one, or a pharmaceutically acceptable salt thereof.

25

10. The compound of Formula **(I)** as claimed in claim 1, wherein the compound is 7-fluoro-1-isopropyl-3-methyl-8-[6-[3-(1-piperidyl)propoxy]-3-pyridyl]imidazo[4,5-c]quinolin-2-one.

30

11. The compound of Formula **(I)** as claimed in claim 1, wherein the compound is a pharmaceutically acceptable salt of 7-fluoro-1-isopropyl-3-methyl-8-[6-[3-(1-piperidyl)propoxy]-3-pyridyl]imidazo[4,5-c]quinolin-2-one.

12. The compound of Formula **(I)** as claimed in claim 1, wherein the compound is 8-[6-[3-(Dimethylamino)propoxy]-3-pyridyl]-7-fluoro-1-isopropyl-3-methyl-imidazo[4,5-c]quinolin-2-one, or a pharmaceutically acceptable salt thereof.
- 5 13. The compound of Formula **(I)** as claimed in claim 1, which is a crystalline form of 7-fluoro-1-isopropyl-3-methyl-8-[6-[3-(1-piperidyl)propoxy]-3-pyridyl]imidazo[4,5-c]quinolin-2-one, which has an X-ray powder diffraction pattern (obtained using copper radiation) with at least two specific peaks at 2-theta = 3.7 and 14.8° plus or minus 0.2° 2-theta.
- 10 14. The compound of Formula **(I)** as claimed in claim 1, which is a crystalline form of 7-fluoro-1-isopropyl-3-methyl-8-[6-[3-(1-piperidyl)propoxy]-3-pyridyl]imidazo[4,5-c]quinolin-2-one, which has an X-ray powder diffraction pattern (obtained using copper radiation) with at least two specific peaks at 2-theta = 3.4 and 11.7° plus or minus 0.2° 2-theta.
- 15 15. A pharmaceutical composition which comprises a compound of Formula **(I)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 14, and at least one pharmaceutically acceptable excipient.
- 20 16. A compound of Formula **(I)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 14, for use in therapy.
- 25 17. A compound of Formula **(I)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 14, for use in the treatment of cancer.

18. A compound of Formula **(I)**, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer according to claim 17, where the compound of Formula **(I)** or a pharmaceutically acceptable salt thereof is to be administered simultaneously, separately or sequentially with radiotherapy.
- 5 19. A compound of Formula **(I)**, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer according to claim 17, where the compound of Formula **(I)** or a pharmaceutically acceptable salt thereof is to be administered simultaneously, separately or sequentially with at least one additional anti-tumour substance selected from the group consisting of doxorubicin, irinotecan, topotecan, etoposide, mitomycin, bendamustine, chlorambucil, cyclophosphamide, ifosfamide, 10 carmustine, melphalan and bleomycin.
20. A compound of Formula **(I)**, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer according to claim 17, where the compound of Formula **(I)**, or a pharmaceutically acceptable salt thereof, is to be administered in combination with at least one additional anti-tumour substance selected from the group consisting of cisplatin, oxaliplatin, carboplatin, valrubicin, idarubicin, doxorubicin, pirarubicin, irinotecan, topotecan, amrubicin, epirubicin, etoposide, 15 mitomycin, bendamustine, chlorambucil, cyclophosphamide, ifosfamide, carmustine, melphalan, bleomycin, olaparib, MEDI4736, AZD1775 and AZD6738.
21. A compound of Formula **(I)** or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer according to any one of claims 17 to 20, wherein said cancer is selected from the group consisting of colorectal cancer, glioblastoma, 25 gastric cancer, ovarian cancer, diffuse large B-cell lymphoma, chronic lymphocytic leukaemia, acute myeloid leukaemia, head and neck squamous cell carcinoma, breast cancer, hepatocellular carcinoma, small cell lung cancer and non-small cell lung cancer.